In this video, health-care analyst David Williamson takes a closer look at Abbott Labs, which has seen its share of headlines this week. There was a big hepatitis C win, a high-profile drug failure, and a potential boost for its blockbuster. Amidst all this news, Wall Street has come out with a new recommendation on the stock. Watch and find out how this affects investors, and what may be the smartest way to play Abbott's spinoff.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article 3 Big Events for 1 Big Pharma originally appeared on Fool.com.
David Williamson and The Motley Fool own shares of Johnson & Johnson. Max Macaluso has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.